Hyposomatotropism blunts lipolysis in abdominally obese women.

What Was Tested

This randomized controlled trial looks at Human Growth Hormone.

It is unclear whether hyposomatotropism in abdominally obese humans is compensated by up-regulation of GH receptor sensitivity or causes less biological effect in target tissues.

The researchers, therefore, determined the responsiveness of adipose tissue to the lipolytic action of GH in abdominally obese (OB) and normal weight (NW) postmenopausal women.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, women only.

How the Study Was Run

The design is described as randomized and placebo-controlled.

The participants were allocated by chance, so the Human Growth Hormone group and the comparison group should start out alike.

The comparison arm used a placebo, so changes seen with Human Growth Hormone could be set against what happens without it.

Lipolysis was measured by infusion of D5-glycerol and modeled as a function of plasma GH concentrations to describe adipose tissue responsiveness.

What Was Measured

The subject headings attached to it are Abdomen, Adipose Tissue, Body Mass Index, Glycerol, Human Growth Hormone, Hypopituitarism and Insulin-Like Growth Factor Binding Protein 3.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Human Growth Hormone.

The publication is from 2002 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the related Exogenous HGH, sermorelin & older GHRPs (why they're passed over) library page, all human trials.